Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
46.11
+0.71 (1.56%)
At close: Nov 11, 2025, 4:00 PM EST
45.22
-0.89 (-1.93%)
After-hours: Nov 11, 2025, 5:01 PM EST
Supernus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts that cover Supernus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $63.25, which forecasts a 37.17% increase in the stock price over the next year. The lowest target is $60 and the highest is $65.
Price Target: $63.25 (+37.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Supernus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 2 | 2 |
| Buy | 0 | 0 | 1 | 1 | 2 | 2 |
| Hold | 2 | 2 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +40.97% | Oct 29, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $45 → $60 | Strong Buy | Maintains | $45 → $60 | +30.12% | Oct 23, 2025 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $40 → $65 | Hold → Buy | Upgrades | $40 → $65 | +40.97% | Oct 9, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $46 → $63 | Buy | Maintains | $46 → $63 | +36.63% | Sep 30, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $36 → $40 | Hold | Maintains | $36 → $40 | -13.25% | Aug 29, 2025 |
Financial Forecast
Revenue This Year
716.65M
from 661.82M
Increased by 8.29%
Revenue Next Year
879.45M
from 716.65M
Increased by 22.72%
EPS This Year
2.70
from 1.32
Increased by 104.52%
EPS Next Year
3.10
from 2.70
Increased by 14.77%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 756.0M | 984.6M | |||
| Avg | 716.7M | 879.5M | |||
| Low | 674.2M | 792.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.2% | 37.4% | |||
| Avg | 8.3% | 22.7% | |||
| Low | 1.9% | 10.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.99 | 4.49 | |||
| Avg | 2.70 | 3.10 | |||
| Low | 2.24 | 0.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 126.7% | 66.5% | |||
| Avg | 104.5% | 14.8% | |||
| Low | 70.0% | -63.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.